Related Experiment Video

Updated: May 28, 2026

Assaying Proteasomal Degradation in a Cell-free System in Plants
07:43

Assaying Proteasomal Degradation in a Cell-free System in Plants

Published on: March 26, 2014

Molecular pathways: targeting proteasomal protein degradation in cancer

Susan M Molineaux1

  • 1Calithera Biosciences, Inc., South San Francisco, California 94080, USA. smolineaux@calithera.com

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|October 25, 2011
PubMed

Insights

The proteasome is a validated cancer target, with new inhibitors in trials. Researchers are investigating if these next-generation proteasome inhibitors offer improved efficacy and safety over existing treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The proteasome's role in protein degradation is crucial for cellular function.
  • Bortezomib's approval validated the proteasome as a key cancer therapeutic target.
  • Ongoing research seeks novel drug targets within the proteasomal pathway.

Purpose of the Study:

  • To explore the potential of next-generation proteasome inhibitors.
  • To evaluate if distinct properties of new inhibitors enhance clinical efficacy and safety.
  • To deepen the understanding of proteasome inhibitor mechanisms in cancer treatment.

Main Methods:

  • Clinical trials of novel proteasome inhibitors.
  • Comparative analysis of efficacy and safety profiles.
  • Mechanistic studies on proteasome inhibition.

Main Results:

  • Next-generation proteasome inhibitors are under clinical investigation.
  • Distinct properties of these inhibitors are being assessed against bortezomib.
  • Efficacy and safety data are pending further clinical evaluation.

Conclusions:

  • The proteasome remains a significant target in cancer therapy.
  • Next-generation inhibitors hold promise for improved cancer treatment outcomes.
  • Further research is essential to elucidate their full therapeutic potential and mechanisms.

More Related Videos

Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae09:05

Cycloheximide Chase Analysis of Protein Degradation in Saccharomyces cerevisiae

Published on: April 18, 2016

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines05:33

High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines

Published on: November 9, 2020

Related Concept Videos

The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Regulated Protein Degradation02:58

Regulated Protein Degradation

It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...